Ameriprise’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.3M Sell
956,961
-296,588
-24% -$8.2M ﹤0.01% 1393
2026
Q2
$42.5M Buy
1,253,549
+500,495
+66% +$16.5M 0.01% 1031
2026
Q1
$24.1M Buy
753,054
+600,785
+395% +$19.6M 0.01% 1286
2025
Q4
$5.34M Buy
152,269
+6,942
+5% +$253K ﹤0.01% 2385
2025
Q3
$4.13M Sell
145,327
-62,754
-30% -$1.5M ﹤0.01% 2572
2025
Q2
$3.77M Buy
208,081
+112,927
+119% +$2.06M ﹤0.01% 2564
2025
Q1
$1.95M Buy
+95,154
New +$2.12M ﹤0.01% 2916

Other funds holding NAMS

Ameriprise's NAMS Position: Q3 2026 in Review

Ameriprise reduced its NewAmsterdam Pharma (NAMS) stake by 24% in Q3 2026, selling an estimated $8.2M and leaving 956,961 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Ameriprise first reported a position in NAMS in Q1 2025 and has held it in 7 quarters since. The position peaked at $42.5M in Q2 2026. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

  • Ameriprise held 956,961 shares of NewAmsterdam Pharma worth $23.3M as of Q3 2026.
  • Ameriprise sold 296,588 NewAmsterdam Pharma shares in Q3 2026, an estimated $8.2M.
  • NewAmsterdam Pharma made up ﹤0.01% of Ameriprise's portfolio in Q3 2026, its #1393 holding.
  • Ameriprise first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 7 quarters since.
  • Ameriprise's NewAmsterdam Pharma position peaked at $42.5M in Q2 2026.
  • 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Ameriprise's 13F filing for Q3 2026, filed 16 Nov 2026.